Advocacy In Action: Who Should Have Molecular Testing When Diagnosed With Lung Cancer?

Vital Options International presents, Advocacy In Action®, bringing together cancer advocacy leadership to address: Lung Cancer Treatment Guidelines & Molecular Testing.

This segment asks the question:  Why are only EFR and ALK are tested for and who should be tested?

Joining Selma Schimmel as co-moderators are:

David R. Spigel, MD – Director, Lung Cancer Research Program at Sarah Cannon Research Institute and a Medical Oncologist at Tennessee Oncology, PLLC, Nashville, TN

Ming S. Tsao, MD, FRCPC – Princess Margaret Cancer Centre, Toronto, Canada

Susan Mantel – VP Programs & Marketing, LUNGevity

Kim Norris – Founder/President, Lung Cancer Foundation Of America

Regina Vidaver, PhD – Executive Director, National Lung Cancer Partnership

Advocacy and educational support provided at ASCO 2013, in part, by:

ASCO 2013 Full Sponsors

 

Comments